Metagil-GV1

Composition: Glimepiride 1 mg + Voglibose 0.2 mg + Metformin 500 mg SR

Metagil GV1 is a triple anti-diabetic combination containing Glimepiride, Voglibose, and Metformin. This powerful formulation targets diabetes through three mechanisms: increasing insulin secretion (Glimepiride), reducing carbohydrate absorption from the intestine (Voglibose), and lowering liver glucose production while improving insulin sensitivity (Metformin). It offers excellent both-meal and fasting sugar control and is commonly prescribed in patients whose sugars are not managed with dual therapy.

Uses:

• Management of Type 2 Diabetes Mellitus
• Strong control of fasting and post-meal sugars
• Reduction of HbA1c levels
• Helpful for patients with high postprandial sugar spikes

Side Effects:

• Hypoglycemia
• Gas, bloating, stomach discomfort (common with Voglibose)
• Diarrhea or nausea
• Dizziness or mild weight gain
• Rare: lactic acidosis

Other Details:

• Should be taken just before meals
• Avoid skipping meals
• Not recommended in severe kidney or liver impairment
• Controls both PPBS and FBS effectively